---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020827"
form_type: "8-K"
ticker: "XFOR"
cik: "0001501697"
company_name: "X4 Pharmaceuticals, Inc"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:47:43.497706+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# X4 Pharma reports Q1 net loss of $51.8M; XOLREMDI approved for WHIM syndrome

## Summary
- Net loss $51.8M vs $24.0M in Q1 2023; includes $13.8M non-cash loss on warrant liability.
- Cash, equivalents, and securities $81.6M as of Mar 31, 2024; runway into 2025 excluding PRV monetization.
- FDA approved XOLREMDI (mavorixafor) for WHIM syndrome in patients 12+ in late April 2024; U.S. launch underway.
- Phase 2 interim data for mavorixafor in chronic neutropenia expected June 2024; Phase 3 trial planned in Q2 2024.
- SG&A expenses rose to $17.4M from $7.2M due to commercial launch preparations.

## SEC filing metadata
- accession: 0001628280-24-020827
- form_type: 8-K
- ticker: XFOR
- cik: 0001501697
- company_name: X4 Pharmaceuticals, Inc
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/0001628280-24-020827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/xfor-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020827
- JSON: https://secwatch.observer/filing/0001628280-24-020827.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020827.txt

## Key facts
- Earnings Releases
  X4 Pharmaceuticals, Inc reported for the first quarter ended March 31, 2024 results: net income $51.8 million.
  - Period: for the first quarter ended March 31, 2024
  - Net income: $51.8 million
  - Result: reported results
  source text: X4 reported a net loss of $51.8 million for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501697/000162828024020827/0001628280-24-020827-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.